论文部分内容阅读
目的探讨自体造血干细胞移植治疗淋巴瘤的临床疗效情况。方法收集2009年12月~2012年12月期间在本院接受自体造血干细胞移植治疗的淋巴瘤患者44例临床资料,对这些患者的临床治疗资料情况进行回顾性总结分析。结果本组44例淋巴瘤患者经自体造血干细胞移植治疗后全部顺利出舱,平均住院时间为(30.21±2.12)天,移植后出现低热5例(11.36%),粒细胞减少2例(4.55%),口腔溃疡6例(13.64%),鼻腔出血1例(2.23%)。经随访三年,本组患者生存36例,死亡8例,生存率为81.82%。结论自体造血干细胞移植在治疗淋巴瘤方面具有确切的临床治疗效果,可显著延长淋巴瘤患者的生存率,值得临床进一步推广应用。
Objective To investigate the clinical efficacy of autologous hematopoietic stem cell transplantation in the treatment of lymphoma. Methods The clinical data of 44 patients with lymphoma undergoing autologous hematopoietic stem cell transplantation in our hospital from December 2009 to December 2012 were collected. The clinical data of these patients were retrospectively analyzed. Results All the 44 patients with lymphoma were successfully exited by autologous hematopoietic stem cell transplantation. The average length of hospital stay was (30.21 ± 2.12) days, 5 cases (11.36%) had hypothermia after transplantation, 2 cases (4.55% ), Oral ulcer in 6 cases (13.64%), nasal bleeding in 1 case (2.23%). After a follow-up of three years, 36 patients survived in this group, 8 died, the survival rate was 81.82%. Conclusion Autologous hematopoietic stem cell transplantation in the treatment of lymphoma has the exact clinical effect, can significantly prolong the survival rate of patients with lymphoma, it is worth further clinical application.